Deer­field launch­es ra­dio­ther­a­py com­pa­ny; UCLA gene edit­ing spin­out se­cures funds

Deer­field on Wednes­day launched a ra­dio­ther­a­py out­fit called Aviko. The new biotech is de­vel­op­ing a ther­a­py known as boron neu­tron cap­ture ther­a­py, or BNCT, which is ap­proved in Japan for head and neck can­cers and is al­so be­ing worked on in Eu­rope.

How­ev­er, the ther­a­py re­quires spe­cial­ized tech­nol­o­gy and cen­ters, and there are cur­rent­ly none in the US. Deer­field VP of Busi­ness De­vel­op­ment and Aviko CEO Dave Green­wald said that the biotech’s ini­tial goals are to es­tab­lish a US BNCT cen­ter and to get in­to the clin­ic in one to two years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA